A Phase 2 interventional study of Brivaracetam in Epilepsy, sponsored by UCB Biopharma S.P.R.L.. Completed at 17 sites in 7 countries. Open to participants aged 1 Month to 16 Years. Per ClinicalTrials.gov, last updated 2022-05-11.
Sponsored by UCB Biopharma S.P.R.L. (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 23rd largest by enrollment, is the only one that started in 2018, is one of 6 in phase 2, and was the 25th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 1 Month to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2018.
This study's enrollment of 50 is close to the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Biopharma S.P.R.L., one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma S.P.R.L. is the lead sponsor of 48 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 12 (80%) have results posted.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 78th largest by enrollment of the 116 interventional ones that give a count, is one of 4 that started in 2018, is one of 26 in phase 2, and was the 114th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of brivaracetam (BRV) administered intravenously (iv) in subjects >= 1 month to \< 16 years of age with epilepsy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brivaracetam will be administered to various age-based cohorts. Cohort 1: Subjects \>=12 to \<16 years; Cohort 2: Subjects \>=6 to \<12 years; Cohort 3: Subjects \>=2 to \<6 years; Cohort 4: Subjects 1 month to \<2 years. Enrollment will be sequential by descending age beginning with Cohort 1. For each cohort, the first half will receive a 15-minute iv infusion. The Data Monitoring Committee (DMC) will then review safety and, as available, PK data to make the following recommendations: the progression of the current cohort (up to 2-minute iv bolus infusion) and progression to initiate enrollment in the preceding cohort.
Drug: Brivaracetam
* Pharmaceutical form: Solution for iv injection * Route of administration: intravenous use * Concentration: 10 mg/ml
Also known as: Briviact
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration - 15 Minutes
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- 15 Minutes
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- 15 Minutes
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 by Infusion Duration- 15 Minutes
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 by Infusion Duration- 15 Minutes
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 by Infusion Duration- 15 Minutes
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- 15 Minutes
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- 15 Minutes
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- 15 Minutes
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration- Bolus
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- Bolus
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- Bolus
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 by Infusion Duration- Bolus
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: At <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 by Infusion Duration- Bolus
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: At 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 by Infusion Duration- Bolus
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: At 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- Bolus
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- Bolus
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- Bolus
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
Time frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)
Number of Participants With Adverse Events (AEs)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.
Time frame: From Screening until last visit (up to Day 68)
Number of Participant Withdrawals Due to Adverse Events
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.
Time frame: From Screening until last visit (up to Day 68)
The study started to enroll participants in June 2018 and concluded in November 2020.
| Milestone | Age Cohort: >=12 to <16 Years | Age Cohort: >=6 to <12 Years | Age Cohort: >=2 to <6 Years | Age Cohort: >=1 Month to <2 Years |
|---|---|---|---|---|
| Started | 12 | 12 | 13 | 13 |
| Completed | 12 | 12 | 13 | 13 |
| Not completed | 0 | 0 | 0 | 0 |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| nanograms per milliliter (ng/mL) | Age Cohort: >=12 to <16 Years (PK-PPS) | Age Cohort: >=6 to <12 Years (PK-PPS) | Age Cohort: >=2 to <6 Years (PK-PPS) | Age Cohort : >=1 Month to <2 Years (PK-PPS) |
|---|---|---|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 | 149.0 (27.6 to 805.1) | NA (NA to NA) | NA (NA to NA) | 310.6 (92.5 to 1042.7) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | Age Cohort: >=12 to <16 Years (PK-PPS) | Age Cohort: >=6 to <12 Years (PK-PPS) | Age Cohort: >=2 to <6 Years (PK-PPS) | Age Cohort : >=1 Month to <2 Years (PK-PPS) |
|---|---|---|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 | 1844.6 (1110.4 to 3064.3) | 2058.8 (1726.4 to 2455.2) | 1774.9 (1087.4 to 2897.1) | 1566.6 (973.1 to 2522.2) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | Age Cohort: >=12 to <16 Years (PK-PPS) | Age Cohort: >=6 to <12 Years (PK-PPS) | Age Cohort: >=2 to <6 Years (PK-PPS) | Age Cohort : >=1 Month to <2 Years (PK-PPS) |
|---|---|---|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 | 1260.6 (962.6 to 1650.8) | 1189.5 (1005.5 to 1407.1) | 1225.3 (676.8 to 2218.6) | 1341.7 (657.9 to 2735.9) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | Age Cohort: >=12 to <16 Years (PK-PPS) | Age Cohort: >=6 to <12 Years (PK-PPS) | Age Cohort: >=2 to <6 Years (PK-PPS) | Age Cohort : >=1 Month to <2 Years (PK-PPS) |
|---|---|---|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 | — | 290.5 (101.2 to 834.0) | — | — |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | Age Cohort: >=12 to <16 Years (PK-PPS) | Age Cohort: >=6 to <12 Years (PK-PPS) | Age Cohort: >=2 to <6 Years (PK-PPS) | Age Cohort : >=1 Month to <2 Years (PK-PPS) |
|---|---|---|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 | — | 2084.3 (681.2 to 6377.0) | — | — |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | Age Cohort: >=12 to <16 Years (PK-PPS) | Age Cohort: >=6 to <12 Years (PK-PPS) | Age Cohort: >=2 to <6 Years (PK-PPS) | Age Cohort : >=1 Month to <2 Years (PK-PPS) |
|---|---|---|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 | — | 1149.8 (613.1 to 2156.4) | — | — |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | Age Cohort: >=12 to <16 Years (PK-PPS) | Age Cohort: >=6 to <12 Years (PK-PPS) | Age Cohort: >=2 to <6 Years (PK-PPS) | Age Cohort : >=1 Month to <2 Years (PK-PPS) |
|---|---|---|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 | — | 466.0 (NA to NA) | 204.5 (0.1 to 383063.7) | 482.9 (4.8 to 48506.1) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | Age Cohort: >=12 to <16 Years (PK-PPS) | Age Cohort: >=6 to <12 Years (PK-PPS) | Age Cohort: >=2 to <6 Years (PK-PPS) | Age Cohort : >=1 Month to <2 Years (PK-PPS) |
|---|---|---|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 | — | 2890.0 (NA to NA) | 1948.8 (690.8 to 5497.7) | 2072.4 (743.2 to 5778.8) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | Age Cohort: >=12 to <16 Years (PK-PPS) | Age Cohort: >=6 to <12 Years (PK-PPS) | Age Cohort: >=2 to <6 Years (PK-PPS) | Age Cohort : >=1 Month to <2 Years (PK-PPS) |
|---|---|---|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 | — | 1820 (NA to NA) | 1203.5 (147.1 to 9847.1) | 727.4 (144.9 to 3652.9) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | 15-minute Infusion (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration - 15 Minutes | NA (NA to NA) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | 15-minute Infusion (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- 15 Minutes | 1903.0 (1474.9 to 2455.4) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | 15-minute Infusion (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- 15 Minutes | 1130.3 (882.1 to 1448.3) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | 15-minute Infusion (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 by Infusion Duration- 15 Minutes | 290.5 (101.2 to 834.0) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | 15-minute Infusion (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 by Infusion Duration- 15 Minutes | 2084.3 (681.2 to 6377.0) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | 15-minute Infusion (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 by Infusion Duration- 15 Minutes | 1149.8 (613.1 to 2156.4) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | 15-minute Infusion (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- 15 Minutes | 776.0 (51.9 to 11611.3) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | 15-minute Infusion (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- 15 Minutes | 2697.8 (1911.1 to 3808.3) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | 15-minute Infusion (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- 15 Minutes | 1030.0 (376.1 to 2820.9) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | Bolus (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration- Bolus | 120.5 (44.7 to 325.2) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | Bolus (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- Bolus | 1704.8 (1237.5 to 2348.4) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | Bolus (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- Bolus | 1383.9 (989.3 to 1935.8) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
No measurements were reported for this outcome.
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
No measurements were reported for this outcome.
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
No measurements were reported for this outcome.
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | Bolus (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- Bolus | 167.5 (9.6 to 2932.2) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | Bolus (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- Bolus | 1531.8 (837.3 to 2802.2) |
Blood samples were taken at indicated time points to determine brivaracetam (BRV) plasma concentration before, during, and after iv BRV administration.
| ng/mL | Bolus (PK-PPS) |
|---|---|
| Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- Bolus | 949.5 (2.8 to 316987.2) |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.
| Participants | Age Cohort: >=12 to <16 Years (SS-iv) | Age Cohort: >=6 to <12 Years (SS-iv) | Age Cohort: >=2 to <6 Years (SS-iv) | Age Cohort: >=1 Month to <2 Years (SS-iv) |
|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 3 | 4 | 7 | 2 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.
| Participants | Age Cohort: >=12 to <16 Years (SS-iv) | Age Cohort: >=6 to <12 Years (SS-iv) | Age Cohort: >=2 to <6 Years (SS-iv) | Age Cohort: >=1 Month to <2 Years (SS-iv) |
|---|---|---|---|---|
| Number of Participant Withdrawals Due to Adverse Events | 0 | 0 | 0 | 0 |
Collected over From Screening until last visit (up to Day 68). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Age Cohort: >=12 to <16 Years (SS-iv) | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Age Cohort: >=6 to <12 Years (SS-iv) | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Age Cohort: >=2 to <6 Years (SS-iv) | 0/13 (0%) | 0/13 (0%) | 7/13 (53.8%) |
| Age Cohort: >=1 Month to <2 Years (SS-iv) | 0/13 (0%) | 1/13 (7.7%) | 2/13 (15.4%) |
| Event | Age Cohort: >=12 to <16 Years (SS-iv) | Age Cohort: >=6 to <12 Years (SS-iv) | Age Cohort: >=2 to <6 Years (SS-iv) | Age Cohort: >=1 Month to <2 Years (SS-iv) |
|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 0/12 | 0/12 | 0/13 | 1/13 |
| Event | Age Cohort: >=12 to <16 Years (SS-iv) | Age Cohort: >=6 to <12 Years (SS-iv) | Age Cohort: >=2 to <6 Years (SS-iv) | Age Cohort: >=1 Month to <2 Years (SS-iv) |
|---|---|---|---|---|
| DizzinessNervous system disorders | 2/12 | 0/12 | 0/13 | 0/13 |
| PyrexiaGeneral disorders | 0/12 | 0/12 | 2/13 | 0/13 |
| Ear infectionInfections and infestations | 0/12 | 0/12 | 2/13 | 0/13 |
| SomnolenceNervous system disorders | 0/12 | 0/12 | 2/13 | 1/13 |
| VomitingGastrointestinal disorders | 0/12 | 1/12 | 0/13 | 0/13 |
| FatigueGeneral disorders | 0/12 | 1/12 | 1/13 | 0/13 |
| PharyngitisInfections and infestations | 1/12 | 0/12 | 0/13 | 0/13 |
| InsomniaPsychiatric disorders | 0/12 | 1/12 | 0/13 | 0/13 |
| PruritusSkin and subcutaneous tissue disorders | 0/12 | 1/12 | 0/13 | 0/13 |
| RashSkin and subcutaneous tissue disorders | 0/12 | 1/12 | 1/13 | 0/13 |
Baseline Characteristics refer to SS-iv, which included study participants who received at least 1 dose of iv BRV.
| Age, Categorical(Participants) | Age Cohort: >=12 to <16 Years | Age Cohort: >=6 to <12 Years | Age Cohort: >=2 to <6 Years | Age Cohort: >=1 Month to <2 Years | Total Title |
|---|---|---|---|---|---|
| <=18 years | 12 | 12 | 13 | 13 | 50 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Age Cohort: >=12 to <16 Years | Age Cohort: >=6 to <12 Years | Age Cohort: >=2 to <6 Years | Age Cohort: >=1 Month to <2 Years | Total Title |
|---|---|---|---|---|---|
| Mean | 13.08 ± 1.16 | 8.33 ± 1.61 | 3.85 ± 0.99 | 0.95 ± 0.59 | 6.39 ± 4.76 |
| Sex: Female, Male(Participants) | Age Cohort: >=12 to <16 Years | Age Cohort: >=6 to <12 Years | Age Cohort: >=2 to <6 Years | Age Cohort: >=1 Month to <2 Years | Total Title |
|---|---|---|---|---|---|
| Female | 6 | 8 | 5 | 5 | 24 |
| Male | 6 | 4 | 8 | 8 | 26 |
| Race/Ethnicity, Customized(Participants) | Age Cohort: >=12 to <16 Years | Age Cohort: >=6 to <12 Years | Age Cohort: >=2 to <6 Years | Age Cohort: >=1 Month to <2 Years | Total Title |
|---|---|---|---|---|---|
| American Indian/Alaskan Native | 0 | 0 | 0 | 2 | 2 |
| Black | 1 | 0 | 0 | 0 | 1 |
| White | 11 | 12 | 13 | 11 | 47 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2018 to primary completion in Nov 2020, 29 months.
Results were first posted in Nov 2021, 1 year after primary completion.
Of 45 industry-sponsored phase 2 interventional studies under Epilepsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 29 months is above that.
Counting every sponsor, half of 66 studies reached it within 23 months; a quarter within 14 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam